Created in 2022, in Marseille, ID SOLUTIONS ONCOLOGY is a 100% owned subsidiary of ID SOLUTIONS created in 2016 by three associates with scientific training, itself located in Montpellier. ID SOLUTIONS ONCOLOGY specializes in diagnostics in vitro in oncology, more particularly, from liquid biopsies, using digital PCR (dPCR).
During the pandemic, ID SOLUTIONS has supplied a large majority of French laboratories with PCR Covid tests, 50 million tests have been produced since 2020, it has been able to triple its turnover in 2021.
In 2022, the biotech therefore created a subsidiary, ID SOLUTIONS ONCOLOGY in Marseille, where it dedicates its activities to oncology and maintains its expertise in infectious diseases in Montpellier. ID SOLUTIONS ONCOLOGY est une société de R&D qui a pour vocation d’accélérer le développement de nouvelles innovations, en particulier le déploiement de ses brevets dédiés à la biopsie liquide, afin d’améliorer la prise en charge et la qualité de vie des malades.
The subsidiary, which was the subject of an investment of 10 million euros, is based in Estaque. Numerous projects are underway in oncology, including clinical studies carried out for two years now at the APHM.